|
1.
|
Franceschi S, Boyle P, Maisonneuve P, La
Vecchia C, Burt AD, Kerr DJ and MacFarlane GJ: The epidemiology of
thyroid carcinoma. Crit Rev Oncog. 4:25–52. 1993.
|
|
2.
|
Reeve TS and Delbridge L: Thyroid cancers
of follicular cell origin. Prog Surg. 19:78–88. 1988.
|
|
3.
|
De Groot LJ, Kaplan EL, McCormick M and
Straus FH: Natural history, treatment, and course of papillary
thyroid carcinoma. J Clin Endocrinol Metab. 71:414–424.
1990.PubMed/NCBI
|
|
4.
|
Samaan NA, Schultz PN, Hickey RC, Goepfert
H, Haynie TP, Johnston DA and Ordonez NG: The results of various
modalities of treatment of well differentiated thyroid carcinomas:
a retrospective review of 1,599 patients. J Clin Endocrinol Metab.
75:714–720. 1992.PubMed/NCBI
|
|
5.
|
Franssila KO: Prognosis of thyroid
carcinoma. Cancer. 36:1138–1146. 1975. View Article : Google Scholar
|
|
6.
|
Ain KB: Anaplastic thyroid carcinoma:
behavior, biology, and therapeutic approaches. Thyroid. 8:715–726.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Giuffrida D and Gharib H: Anaplastic
thyroid carcinoma: current diagnosis and treatment. Ann Oncol.
11:1083–1089. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Pardoll D and Allison J: Cancer
immunotherapy: breaking the barriers to harvest the crop. Nat Med.
10:887–902. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Gabrilovich DI and Nagaj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ostrand-Rosenberg S and Sinha P:
Myeloid-derived suppressor cells: linking inflammation and cancer.
J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Zea AH, Rodriguez PC, Atkins MB, Hernandez
C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A,
O’Neill A and Ochoa AC: Arginase-producing myeloid suppressor cells
in renal cell carcinoma patients: a mechanism of tumor evasion.
Cancer Res. 65:3044–3048. 2005.PubMed/NCBI
|
|
13.
|
Ochoa AC, Zea AH, Hernandez C and
Rodriguez PC: Arginase, prostaglandins, and myeloid-derived
suppressor cells in renal cell carcinoma. Clin Cancer Res.
13:721s–726s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Diaz-Montero CM, Salem ML, Nishimura MI,
Garett-Mayre E, Cole DJ and Montero AJ: Increased circulating
myeloid-derived suppressor cells correlate with clinical cancer
stage, metastatic tumor burden, and doxorubicin-cyclophosphamide
chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar
|
|
15.
|
Gabitass RF, Annels NE, Crawshaw J, Pandha
HS and Middleton GE: Use of gemcitabine-(GEM) and
fluoropyrimidine-based chemotherapy to reduce myeloid-derived
suppressor cells (MDSCs) in pancreatic (PC) and esophago-gastric
cancer (EGC) (abs. 2588). In: Proceedings of the 2011 Annual
meeting of Am Soc Clin Oncol; 3–7 June 2011; Chicago
|
|
16.
|
Ohki S, Shibata M, Gonda K, Machida T,
Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H and
Takenoshita S: Circulating myeloid-derived suppressor cells are
increased and correlate to immune suppression, inflammation and
hypoalbuminemia in patients with cancer. Oncol Rep. 28:453–458.
2012.PubMed/NCBI
|
|
17.
|
Moore KW, de Waal Malefyt R, Coffmann RL
and O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu
Rev Immunol. 19:683–765. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Blackwill F and Mantovani A: Cancer and
inflammation: implications for pharmacology and therapeutics. Clin
Pharmacol Ther. 87:401–406. 2010. View Article : Google Scholar
|
|
19.
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Enomoto T, Sugawa H, Inoue T, Miyamoto M,
Kosugi S, Takahashi T, Kitamura N, Yamamoto I, Konishi J, Mori T
and Imura H: Establishment of a human undifferentiated human
thyroid carcinoma cell line producing several growth factors and
cytokines. Cancer. 65:1971–1979. 1990. View Article : Google Scholar
|
|
21.
|
Iwasa K, Noguchi M, Mori K, Ohta N,
Miyazaki I, Nonomura A, Mizukami Y, Nakamura S and Michigishi T:
Anaplastic thyroid carcinoma producing the granulocyte colony
stimulating factor (G-CSF): report of a case. Surg Today.
25:158–160. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Murabe H, Akamizu T, Kubota A and Kusaka
S: Anaplastic thyroid carcinoma with prominent cardiac metastasis
accompanied by a marked leukocytosis with a neutrophilia and high
GM-CSF level in serum. Intern Med. 31:1107–1111. 1992. View Article : Google Scholar
|
|
23.
|
Allin KH, Bojesen SE and Nordestgaard BG:
Baseline C-reactive protein is associated with incident cancer and
survival in patients with cancer. J Clin Oncol. 27:2217–2224. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Chen HH, Chen IH, Liao CT, Wei FC, Lee LY
and Huang SF: Preoperative circulating C-reactive protein levels
predict pathological aggressiveness in oral squamous cell
carcinoma: a retrospective clinical study. Clin Otolaryngol.
36:147–153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Il’yasova D, Colbert LH, Harris TB, Newman
AB, Bauer DC, Satterifield S and Kritchevsky SB: Circulating levels
of inflammatory markers and cancer risk in the health aging and
body comparison cohort. Cancer Epidemiol Biomarkers Prev.
14:2413–2418. 2005.PubMed/NCBI
|
|
26.
|
Erlinger TP, Platz EA, Rifai N and
Helzlsouer KJ: C-reactive protein and the risk of incident
colorectal cancer. JAMA. 291:585–590. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kao J, Ko EC, Eisenstein S, et al:
Targeting immune suppressing myeloid-derived suppressor cells in
oncology. Cri Rev Oncol Hematol. 77:12–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
